Assessing the value, challenges and collaboration networks of hospital Real World Data for pharmaceutical companies

Abstract

The first aim of the current research is to assess the value, hurdles and collaboration models of Real-World Data (RWD)/Real-World Evidence (RWE) for pharmaceutical companies. Shortly said, RWD/RWE provide data and evidence on patients collected in a real-world setting rather than under controlled research circumstances. RWD/RWE were unexplored for a long time but have increasingly been finding their way into many use cases for pharmaceutical companies and the healthcare sector at large (see further, cf. Sections 2.2, 4.1, 5.1). RWD/RWE is something new, and therefore its value for pharmaceutical companies (especially in Belgium), is to date largely unexplored and many research gaps exist (i.e. what collaboration models do pharma companies want?). The second aim of the paper is to develop a blueprint for a collaboration model between pharmaceutical companies and hospitals for the exchange of RWD/RWE. The third aim is to assess LynxCare’s strategic value for the pharmaceutical industry. LynxCare is a startup that provides data mining solutions for hospital RWD/RWE.